US court denies Teva’s final shot at blocking Copaxone copies

A US district court has dismissed Teva’s case against the US Food and Drug Administration (FDA) aimed at stopping the administration from approving generic versions of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk